FDA's TEMPO Pilot Speeds Up Safe Digital Health Device Access
Published Date: 12/8/2025
Notice
Summary
The FDA is launching the TEMPO pilot to help get cool digital health devices to patients faster while keeping safety a top priority. Starting January 2, 2026, device makers can apply to join this program, which ties payments to real health improvements for people with chronic diseases. This means better care, new tech, and smarter spending for patients and providers alike!
Analyzed Economic Effects
5 provisions identified: 3 benefits, 1 costs, 1 mixed.
Possible Enforcement Discretion for Participants
Manufacturers may ask FDA to exercise enforcement discretion so FDA will not enforce certain legal requirements when their device is offered to or by CMMI ACCESS participants for an intended use to improve patient outcomes. FDA lists examples such as premarket authorization requirements, investigational device exemption (IDE) requirements, and requirements under 21 CFR parts 50 and 56.
Required Real-World Data Collection and Reporting
Manufacturers participating in the TEMPO pilot are expected to collect real-world data (RWD) about their device's intended use, share those data with FDA during participation, and use the data to seek marketing authorization. FDA also requests proposed interim reporting (for example, every 6 months) to report adverse events, new risks, and progress.
Limited US-Based Participant Slots
FDA currently expects to select up to about ten manufacturers based in the United States in each of four clinical use areas for the TEMPO pilot. FDA intends to select U.S.-based manufacturers to facilitate oversight such as inspections and access to records.
Pilot Focus on Four Clinical Use Areas
FDA will consider devices intended for clinician-supervised outpatient treatment in these four clinical use areas: (1) early cardio-kidney-metabolic (hypertension, dyslipidemia, obesity or overweight with marker of central obesity, or prediabetes); (2) cardio-kidney-metabolic (diabetes, chronic kidney disease, or atherosclerotic cardiovascular disease); (3) musculoskeletal (chronic musculoskeletal pain); and (4) behavioral health (depression or anxiety).
Applications Open January 2, 2026
If you make digital health devices, you can submit a "Statement of Interest for Participation in the TEMPO Pilot" starting January 2, 2026. FDA says it will begin follow-up requests to potential participants around March 2, 2026.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10321 — Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Safety and Effectiveness of MFLUSIVA (Influenza Vaccine, mRNA) Manufactured by Moderna TX Inc.
The FDA is holding a public meeting on June 18, 2026, to talk about the safety and effectiveness of MFLUSIVA, a new flu vaccine made by Moderna. Anyone can watch online and share their thoughts before June 17. This is a big deal for people who get flu shots and could affect how this vaccine is used and approved.
2026-10295 — M11 Clinical Electronic Structured Harmonised Protocol (CeSHarP); International Council for Harmonisation; Guidance for Industry; Availability
The FDA just released a new, easy-to-use digital guide called M11 CeSHarP to help everyone involved in clinical trials share and review study plans faster and clearer. This affects drug companies, researchers, and regulators worldwide by setting a global standard for how trial info is written and shared electronically. The new rules kick in now, aiming to save time and reduce confusion, with no direct cost but big efficiency gains.
2026-10277 — Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability
The FDA just released new draft guides to help drug makers design studies proving their generic drugs work like the originals. If you’re in the drug business, now’s your chance to share feedback by July 21, 2026, before these guides become final. These updates aim to speed up drug approvals, potentially saving time and money for companies and patients alike!
2026-10284 — Protein Efficiency Ratio Rat Bioassay Studies To Demonstrate That a New Infant Formula Supports the Quality Factor of Sufficient Biological Quality of Protein; Guidance for Industry; Availability
The FDA just released new guidance to help baby formula makers prove their products have good-quality protein using special rat studies. This update affects formula manufacturers and labs, making it easier and clearer to show their formulas meet nutrition standards. The guidance is effective now, helping companies avoid costly mistakes and speed up getting new formulas to market.
2026-10268 — Notice of Decision Not To Designate Hepatitis Delta Virus Diseases as an Addition to the Current List of Tropical Diseases in the Federal Food, Drug, and Cosmetic Act
The FDA decided not to add Hepatitis Delta Virus (HDV) to the list of tropical diseases because it doesn’t fully meet the rules about market size and who it affects. This means drug makers won’t get special priority review vouchers for HDV treatments right now. People working on HDV drugs should keep an eye out for future updates but won’t see changes or new incentives immediately.
2026-10190 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Patent Term Restoration; Due Diligence Petitions; Filing, Format, and Content of Petitions
The FDA is updating how companies ask for extra patent time when their new drugs or devices take a while to get approved. This affects drug and medical device makers who want to protect their inventions longer. Comments on these changes are open until June 22, 2026, and the update aims to keep the process clear without adding extra costs or delays.
Previous / Next Documents
Previous: 2025-22188 — Agency Information Collection Activities: Proposed Collection; Comment Request
The Centers for Medicare & Medicaid Services (CMS) wants your thoughts on their plan to collect some info from the public. They’re asking for comments by February 6, 2026, to make sure the process is clear, useful, and not too much work. This affects anyone who might provide info to CMS and helps keep things running smoothly without wasting time or money.
Next: 2025-22191 — Agency Information Collection Activities: Requests for Comments; Clearance of Renewed Approval of Information Collection: FAA Advisory Circular 120-119, Voluntary Safety Management System for Other Regulated Entities Transporting Dangerous Goods by Air
The FAA is renewing approval for a voluntary safety program that helps companies safely transport dangerous goods by air. This affects businesses that choose to follow FAA safety guidelines and submit their safety plans for review. Comments on this renewal are open until January 7, 2026, with no new fees or major changes involved.